tiprankstipranks
Advertisement
Advertisement

GKOS Stock Latest News

Seaport Research med technology analyst holds analyst/industry conference call
The FlySeaport Research med technology analyst holds analyst/industry conference call
5d ago
GKOS
Glaukos announces commercial availability of Epioxa HD/Epioxa
PremiumThe Fly
Glaukos announces commercial availability of Epioxa HD/Epioxa
10d ago
GKOS
Glaukos management to meet with Piper Sandler
PremiumThe Fly
Glaukos management to meet with Piper Sandler
17d ago
GKOS
Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update
PremiumCompany Announcements
Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update
27d ago
8K
GKOS
Glaukos Expands Eye Care Pipeline With New GLK-321 Trial in Demodex Blepharitis
PremiumCompany Announcements
Glaukos Expands Eye Care Pipeline With New GLK-321 Trial in Demodex Blepharitis
30d ago
GKOS
Glaukos Refines Glaucoma Implant Delivery With New Inserter Study
PremiumCompany AnnouncementsGlaukos Refines Glaucoma Implant Delivery With New Inserter Study
30d ago
GKOS
AI Adoption Raises Operational, Regulatory, and Reputational Risks for Glaukos Corp.
Premium
Company Announcements
AI Adoption Raises Operational, Regulatory, and Reputational Risks for Glaukos Corp.
1M ago
GKOS
Glaukos Corp. Earnings Call Signals High-Growth Phase
Premium
Company Announcements
Glaukos Corp. Earnings Call Signals High-Growth Phase
1M ago
GKOS
Glaukos price target raised to $127 from $125 at Needham
PremiumThe Fly
Glaukos price target raised to $127 from $125 at Needham
1M ago
GKOS
Glaukos (GKOS): Strong Execution, Expanding iDose Adoption, and De‑Risked Pipeline Support Buy Rating and $131 Target
PremiumRatings
Glaukos (GKOS): Strong Execution, Expanding iDose Adoption, and De‑Risked Pipeline Support Buy Rating and $131 Target
1M ago
GKOS
Glaukos: Strengthening Growth, Epioxa Momentum, and Justified Premium Valuation Support Buy Rating
PremiumRatings
Glaukos: Strengthening Growth, Epioxa Momentum, and Justified Premium Valuation Support Buy Rating
1M ago
GKOS
Glaukos price target raised to $135 from $122 at Wells Fargo
PremiumThe Fly
Glaukos price target raised to $135 from $122 at Wells Fargo
1M ago
GKOS
Closing Bell Movers: Palo Alto Networks down 8% on soft guidance
PremiumThe FlyClosing Bell Movers: Palo Alto Networks down 8% on soft guidance
1M ago
CE
ADI
Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook
Premium
Company Announcements
Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook
1M ago
8K
GKOS
Glaukos reports Q4 adjusted EPS (28c), consensus (30c)
Premium
The Fly
Glaukos reports Q4 adjusted EPS (28c), consensus (30c)
1M ago
GKOS
Glaukos sees FY26 revenue $600M-$620M, consensus $613.35M
PremiumThe Fly
Glaukos sees FY26 revenue $600M-$620M, consensus $613.35M
1M ago
GKOS
Notable companies reporting after market close
PremiumThe Fly
Notable companies reporting after market close
1M ago
TOL
CDNS
GKOS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
GKOS Earnings this Week: How Will it Perform?
1M ago
GKOS
Glaukos assumed with an Outperform at William Blair
PremiumThe Fly
Glaukos assumed with an Outperform at William Blair
2M ago
GKOS
Glaukos price target raised to $131 from $123 at BTIG
PremiumThe FlyGlaukos price target raised to $131 from $123 at BTIG
2M ago
GKOS
Wells sees potential upside after Glaukos’ iDose repeat dosing label approved
Premium
The Fly
Wells sees potential upside after Glaukos’ iDose repeat dosing label approved
2M ago
GKOS
Glaukos announces FDA approval of iDose TR NDA labeling supplement
Premium
The Fly
Glaukos announces FDA approval of iDose TR NDA labeling supplement
2M ago
GKOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >